DOI QR코드

DOI QR Code

Serum Level of Mast Cell Tryptase in Patients with Oral Squamous Cell Carcinoma: Lack of Correlation with Clinicopathologic Factors

  • Jaafari-Ashkavandi, Zohreh (Department of Oral and Maxillofacial Pathology, Institute for Cancer Research, Shiraz University of Medical Sciences) ;
  • Khademi, Bijan (Department of Otolaryngology and Head and Neck Surgery, Institute for Cancer Research, Shiraz University of Medical Sciences) ;
  • Akbari, Somayeh (School of Dentistry, Shiraz University of Medical Sciences) ;
  • Malekzadeh, Mahyar (Institute for Cancer Research, Shiraz University of Medical Sciences)
  • Published : 2013.05.30

Abstract

Background: Mast cells can influence tumor progression via different pathways and increased mast cell density has been demonstrated in oral squamous cell carcinoma (OSCC). It has been shown that the serum tryptase level is elevated with some malignant tumours and may thus be a useful parameter. However, there are no data available about OSCC. The main aim of this study was the evaluation of mast cell tryptase (MCT) level in OSCC patient serum. Materials and Methods: In this cross-sectional, analytic study, the circulating levels of MCT were assessed in sera of 55 OSCC patients and 34 healthy individuals with ELISA technique. Results: The serum MCT level in OSCC patients was 12-14 ng/ml, which was not significantly higher than the healthy control group. While the serum level of MCT was higher with larger tumours, there was no apparent correlation with clinico-pathological features such as patient age, gender, tumor location, stage, nodal status, distant metastasis, histological grade and smoking. Conclusions: Our findings showed that despite the results obtained from studies of other malignant tumors, serum level of MCT in OSCC patients could not be a credited as a reliable indicator of the presence or progression of tumours.

Keywords

Mast cell;tryptase;serum;oral;head and neck;squamous cell carcinoma

References

  1. Coussens LM, Raymond WW, Bergers G, et al (1999). Inflammatory mast cells up- regulates angiogenesis during squamous epithelial carcinogenesis. Genes Dev, 13, 1382-97. https://doi.org/10.1101/gad.13.11.1382
  2. Elpek G, Gelen T (2001). The prognostic relevance of angiogenesis and mast cells in SCC of the esophagus. J Clin Pathol, 54, 940-4. https://doi.org/10.1136/jcp.54.12.940
  3. Fukushima H, Ohsawa M, Ikura Y, et al (2006). Mast cells in diffuse large B-cell lymphoma; their role in fibrosis. Histopathology, 49, 498-505. https://doi.org/10.1111/j.1365-2559.2006.02534.x
  4. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al (2005). Mast cells as “tunable” effector and immunoregulatory cells: Recent advances. Annu Rev Immunol, 23, 749-86. https://doi.org/10.1146/annurev.immunol.21.120601.141025
  5. Galli SJ, Nakae S, Tsai M (2005). Mast cells in the development of adaptive immune responses. Nat Immunol, 6, 135-42. https://doi.org/10.1038/ni1158
  6. Hogan AD, Schwartz LB (1997). Markers of mast cell degranulation. Method, 13, 43-52. https://doi.org/10.1006/meth.1997.0494
  7. Iamaroon A, Surawut P, Sumana J (2003). Increase of mast cell and tumor angiogenesis in oral squamous cell carcinoma. J Oral Pathol Med, 32, 195-9. https://doi.org/10.1034/j.1600-0714.2003.00128.x
  8. Jaafari-Ashkavandi Z, Moshref M, Mashhadi-Abbas F, Sargolzaie S, Taghavi N (2010). Evaluation of CD31 expression and mast cell count in dysplastic lesions and squamous cell carcinoma of the oral cavity. Iran Red Crescent Med J, 12, 272-6
  9. Messadi DV, Wilder-Smith P, Wolinsky L (2009). Improving oral cancer survival: the role of dental providers. J Calif Dent Assoc, 37, 789-98.
  10. Nechushtan H (2010). The complexity of the complicity of mast cells in cancer. Int J Biochem Cell Biol, 42, 551-4 https://doi.org/10.1016/j.biocel.2009.12.015
  11. Norrby K (2002). Mast cell and angiogenesis. APMIS, 110, 355-71. https://doi.org/10.1034/j.1600-0463.2002.100501.x
  12. Artuc M, Steckelings M, Henz BM (2002). Mast cell–fibroblast interactions: human mast cells as source and inducer of fibroblast and epithelial growth factors. J Invest Dermatol, 118, 391-5. https://doi.org/10.1046/j.0022-202x.2001.01705.x
  13. Cheema VS, Ramesh V, Balamurali PD (2012). The relevance of mast cells in oral squamous cell carcinoma. J Clin Diagn Res, 6, 1803-7.
  14. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST (2006). Mast cells and cutaneous malignancies. Mod Pathol, 19, 149-59.
  15. Oliveira-Neto HH, Leite AF, Costa NL, et al (2007). Decrease in mast cells in oral squamous cell carcinoma: possible failure in the migration of these cells. Oral Oncol, 43, 484-90. https://doi.org/10.1016/j.oraloncology.2006.05.004
  16. Rajput AB, Turbin DA, Cheang MC, et al (2008). Stromal mast cells in invasive breast cancer are a marker of favorable prognosis: a study of 4,444 cases. Breast Cancer Res Treat, 107, 249-57. https://doi.org/10.1007/s10549-007-9546-3
  17. Ribatti D, Crivellato E (2009). The controversial role of mast cells in tumor growth. Int Rev Cell Mol Biol, 275, 89-131. https://doi.org/10.1016/S1937-6448(09)75004-X
  18. Ribatti D, Ennas MG, Vacca A, et al (2003). Tumor vascularity and tryptase positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest, 33, 420-5. https://doi.org/10.1046/j.1365-2362.2003.01152.x
  19. Rojas IG, Spencer ML, Martinez SL, et al (2005). Characterization of mast cells subpopulation in lip cancer. J Oral Path Med, 34, 268-273. https://doi.org/10.1111/j.1600-0714.2004.00297.x
  20. Rueff F, Przybilla B, Bilo MB, et al (2010). Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol, 126, 105-11. https://doi.org/10.1016/j.jaci.2010.04.025
  21. Samoszuk M, Corwin MA (2003). Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. Int J Cancer, 107, 159-63. https://doi.org/10.1002/ijc.11340
  22. Sayed BA, Christy A, Quirion MR, Brown MA (2008). The master switch: The role of mast cells in autoimmunity and tolerance. Annu Rev Immunol, 26, 705-39. https://doi.org/10.1146/annurev.immunol.26.021607.090320
  23. Sperr WR, Jordan JH, Baghestanian M, et al (2001). Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood, 98, 2200-9. https://doi.org/10.1182/blood.V98.7.2200
  24. Strouch MJ, Cheon EC, Salabat MR, et al (2010). Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res, 16, 2257-65. https://doi.org/10.1158/1078-0432.CCR-09-1230
  25. Tayebi-Meybodi N, Javidi Z, Esmaili HA, Nahidi Y (2007). Mast cells and histopathologic variants of basal cell carcinoma. Iran J Dermatol, 10, 135-41.
  26. Tinge B, Molin D, Bergqvist M, Ekman S, Bergstrom S (2010). Mast cells in squamous cell esophageal carcinoma and clinical parameters. Cancer Genomics Proteomics, 7, 25-9.
  27. Valent P, Horny HP, Triggiani M, Arock M (2011). Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. Int Arch Allergy Immunol, 156, 119-27. https://doi.org/10.1159/000323763
  28. Xiang M, Gu Y, Zhao F, et al (2020). Mast cell tryptase promotes breast cancer migration and invasion. Oncol Rep, 23, 615-9.

Cited by

  1. The serum tryptase test: an emerging robust biomarker in clinical hematology vol.7, pp.5, 2014, https://doi.org/10.1586/17474086.2014.955008